Jump Financial LLC Has $14.74 Million Position in Boston Scientific Co. (NYSE:BSX)

Jump Financial LLC trimmed its holdings in Boston Scientific Co. (NYSE:BSX - Free Report) by 42.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 164,977 shares of the medical equipment provider's stock after selling 121,091 shares during the quarter. Jump Financial LLC's holdings in Boston Scientific were worth $14,736,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. TFC Financial Management Inc. raised its holdings in Boston Scientific by 308.8% during the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 210 shares in the last quarter. Global Wealth Strategies & Associates raised its position in Boston Scientific by 423.7% in the fourth quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock worth $28,000 after acquiring an additional 250 shares in the last quarter. West Oak Capital LLC bought a new position in shares of Boston Scientific during the 4th quarter valued at about $29,000. Valley National Advisers Inc. raised its holdings in shares of Boston Scientific by 262.4% in the 4th quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock worth $35,000 after purchasing an additional 286 shares in the last quarter. Finally, Fairway Wealth LLC acquired a new stake in Boston Scientific during the fourth quarter valued at approximately $36,000. Institutional investors own 89.07% of the company's stock.

Boston Scientific Stock Performance

Boston Scientific stock traded down $0.17 on Friday, reaching $95.08. 6,672,959 shares of the stock were exchanged, compared to its average volume of 6,370,413. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. The firm has a fifty day moving average price of $99.68 and a two-hundred day moving average price of $94.26. The stock has a market cap of $140.63 billion, a PE ratio of 76.06, a PEG ratio of 2.79 and a beta of 0.73. Boston Scientific Co. has a twelve month low of $66.80 and a twelve month high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. Sell-side analysts anticipate that Boston Scientific Co. will post 2.85 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on BSX shares. Royal Bank of Canada increased their price objective on Boston Scientific from $105.00 to $116.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. Truist Financial dropped their price target on Boston Scientific from $120.00 to $113.00 and set a "buy" rating on the stock in a research note on Friday, April 11th. Piper Sandler lifted their target price on shares of Boston Scientific from $95.00 to $115.00 and gave the stock an "overweight" rating in a research report on Monday, February 3rd. Argus set a $130.00 price objective on shares of Boston Scientific in a research note on Tuesday, February 18th. Finally, Barclays increased their target price on Boston Scientific from $111.00 to $118.00 and gave the company an "overweight" rating in a report on Monday, February 10th. One equities research analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $110.22.

Insider Activity at Boston Scientific

In other news, EVP Jeffrey B. Mirviss sold 4,675 shares of the business's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $104.25, for a total transaction of $487,368.75. Following the sale, the executive vice president now directly owns 28,454 shares in the company, valued at approximately $2,966,329.50. The trade was a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP John Bradley Sorenson sold 1,201 shares of Boston Scientific stock in a transaction on Friday, February 14th. The stock was sold at an average price of $106.31, for a total transaction of $127,678.31. Following the sale, the executive vice president now owns 25,443 shares in the company, valued at $2,704,845.33. This represents a 4.51 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 133,183 shares of company stock worth $13,948,476. Company insiders own 0.50% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.